The research interest of William A. Faubion, M.D., is the pathophysiology and novel therapeutics of Crohn's disease and ulcerative colitis, collectively referred to as inflammatory bowel disease (IBD). In collaboration with patients seen in the IBD clinic, Dr. Faubion's team utilizes discovery platforms (omic technologies) to develop hypotheses about disease mechanisms to test in the laboratory using cell lines or animal systems. This team of scientists and generous patients has built a collection of clinical data linked to biological samples in which to explore individualized approaches to therapy.
- Epigenetics of T cell-fate decisions leading to intestinal inflammation
- T regulatory cell biology in intestinal inflammation
- Cell therapy of IBD
- Clinical trial conduct and design
- Systems biology approach to IBD
Significance to patient care
IBD is a heterogeneous disease with a precise molecular fingerprint. Dr. Faubion's team works to identify and classify patients with a unique molecular identity to improve prognosis and precision therapy. The team's work on cell therapy in fistulizing disease has already led to breakthroughs in therapy for this highly morbid condition.